阿贝西利联合内分泌治疗用于HR+、HER2-、淋巴结阳性高危早期乳腺癌辅助治疗(monarchE)
monarchE是一项开放标签III期研究,纳入HR+、HER2-高危早期乳腺癌患者,随机接受标准辅助内分泌治疗联合或不联合阿贝西利(150mg每日两次,共2年)。
要点
- 阿贝西利联合内分泌治疗显著改善高危早期乳腺癌的无侵袭性疾病生存。
- 2年IDFS率联合组92.2%,单药组88.7%,风险比0.75。
- 安全性特征与阿贝西利已知安全性一致。
核心结论
- 阿贝西利联合内分泌治疗是首个在HR+、HER2-淋巴结阳性高危早期乳腺癌中显著改善IDFS的CDK4/6抑制剂。
研究设计与样本
- 开放标签III期研究,纳入HR+、HER2-高危早期乳腺癌患者,随机1:1接受标准辅助内分泌治疗联合或不联合阿贝西利(150mg每日两次,共2年)。
主要发现
- 预设中期分析时,5637例随机患者中观察到323例IDFS事件。
- 2年IDFS率联合组为92.2%,单药组为88.7%。
- 安全性数据与阿贝西利已知安全性特征一致。
关键数值与推荐
- 入组标准:≥4个阳性淋巴结,或1-3个阳性淋巴结且肿瘤大小≥5cm、组织学分级3级或中心检测Ki-67≥20%。
- 阿贝西利剂量为150mg每日两次,持续2年。
临床怎么用
- 对于HR+、HER2-淋巴结阳性高危早期乳腺癌患者,可考虑在标准辅助内分泌治疗基础上加用阿贝西利2年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Many patients with HR+, HER2- early breast cancer (EBC) will not experience recurrence or have distant recurrence with currently available standard therapies. However, up to 30% of patients with high-risk clinical and/or pathologic features may experience distant recurrence, many in the first few years. Superior treatment options are needed to prevent early recurrence and development of metastases for this group of patients. Abemaciclib is an oral, continuously dosed, CDK4/6 inhibitor approved for HR+, HER2- advanced breast cancer (ABC). Efficacy and safety of abemaciclib in ABC supported evaluation in the adjuvant setting. METHODS: This open-label, phase III study included patients with HR+, HER2-, high-risk EBC, who had surgery and, as indicated, radiotherapy and/or adjuvant/neoadjuvant chemotherapy. Patients with four or more positive nodes, or one to three nodes and either tumor size ≥ 5 cm, histologic grade 3, or central Ki-67 ≥ 20%, were eligible and randomly assigned (1:1) to standard-of-care adjuvant endocrine therapy (ET) with or without abemaciclib (150 mg twice daily for 2 years). The primary end point was invasive disease-free survival (IDFS), and secondary end points included distant relapse-free survival, overall survival, and safety. RESULTS: At a preplanned efficacy interim analysis, among 5,637 randomly assigned patients, 323 IDFS events were observed in the intent-to-treat population. Abemaciclib plus ET demonstrated superior IDFS versus ET alone (P = .01; hazard ratio, 0.75; 95% CI, 0.60 to 0.93), with 2-year IDFS rates of 92.2% versus 88.7%, respectively. Safety data were consistent with the known safety profile of abemaciclib. CONCLUSION: Abemaciclib when combined with ET is the first CDK4/6 inhibitor to demonstrate a significant improvement in IDFS in patients with HR+, HER2- node-positive EBC at high risk of early recurrence.
引用
- Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol. 2020. PMID: 32954927. doi:10.1200/JCO.20.02514
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。